Skip to main content

Table 1 Medians of circulating immune cells in mCRC patient subgroups

From: Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness

 

mCRC

Primary tumor location

KRAS status

right c.

left c.

r.s./rectum

KRAS wt

KRAS mut

Lymphocytes (cells/μL)

1445

1593

1469

1309

1521

 

1312

CD3+ in lymphocytes (%)

63

65

71

59

64

 

65

T cell count (cells/μL)

1042

1137

1151

894

1220

 

894

CD8+ in T cells (%)

44

38

44

48

45

*

38

CD8+ count (cells/μL)

380

372

511

401

558

 

309

Treg in lymphocytes (%)

1.9

1.7

2.0

2.0

2.3

 

1.7

Treg in CD4+ (%)

6.2

5.3

6.5

7.2

7.0

**

4.4

Treg count (cells/μL)

26.5

33.0

37.9

25.4

38.5

*

23.0

CD8:Treg

13.1

10.9

13.3

15.7

11.5

 

14.0

  1. Stars indicate statistically significant difference in mCRC patients between respective subgroups: *p < 0.05, ** p < 0.005. c, colon; r.s., rectosigma